Certolizumab pegol, CAS 428863-50-7

Product Description: Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research[1][2].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs. 2013 Jan;73(1):75-97./[2]Nesbitt A, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007 Nov;13(11):1323-32./[3]Kosekli MA, et al. Effects of Certolizumab on Cerulein-Induced Acute Pancreatitis in Rats. Pancreas. 2016 Sep;45(8):1120-5.

CAS Number: 428863-50-7

Molecular Weight: N/A

Compound Purity: 99.30

Research Area: Inflammation/Immunology; Cancer

Solubility: H2O

Target: TNF Receptor

• Artikelnummer: MEXHY-P9953-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9953-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated